Clinical trial
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in…
NCT00395460 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00395460 |
|---|---|
| Title | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients |
| Official title | A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Central Nervous System Diseases |
| Intervention type | Drug |
| Interventions | Gadobutrol (Gadavist, Gadovist, BAY86-4875), Magnevist |
| Enrollment | 147 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Nov 3, 2006 |
| Last update posted | Jun 8, 2015 |
| Countries | China |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: